Bokhari says the offering comes as the Canadian company actively works to submit an Investigational New Drug Application to the FDA to use its FSD201 as a possible treatment to reduce lung inflammation in hospitalized coronavirus patients.
FSD Pharma says $10M in new capital is 'gratifying' as the firm makes progress in coronavirus trial
Quick facts: FSD Pharma
Price: 2.38 CAD
Market Cap: $45.6 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE